Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Cardiometabolic risk assessment: an approach to the prevention of cardiovascular disease and diabetes mellitus.

Vasudevan AR, Ballantyne CM.

Clin Cornerstone. 2005;7(2-3):7-16. Review.

PMID:
16473256
2.

Cardiovascular disease and modifiable cardiometabolic risk factors.

Cannon CP.

Clin Cornerstone. 2007;8(3):11-28. Review.

PMID:
18452839
3.

Cardiovascular disease and modifiable cardiometabolic risk factors.

Cannon CP.

Clin Cornerstone. 2008;9(2):24-38; discussion 39-41.

PMID:
19410160
4.

Identification and management of cardiometabolic risk in Canada: a position paper by the cardiometabolic risk working group (executive summary).

Cardiometabolic Risk Working Group: Executive Committee, Leiter LA, Fitchett DH, Gilbert RE, Gupta M, Mancini GB, McFarlane PA, Ross R, Teoh H, Verma S, Anand S, Camelon K, Chow CM, Cox JL, Després JP, Genest J, Harris SB, Lau DC, Lewanczuk R, Liu PP, Lonn EM, McPherson R, Poirier P, Qaadri S, Rabasa-Lhoret R, Rabkin SW, Sharma AM, Steele AW, Stone JA, Tardif JC, Tobe S, Ur E.

Can J Cardiol. 2011 Mar-Apr;27(2):124-31. doi: 10.1016/j.cjca.2011.01.016. Review.

PMID:
21459258
6.

The metabolic syndrome: diagnosis and treatment.

Zieve FJ.

Clin Cornerstone. 2004;6 Suppl 3:S5-13. Review.

PMID:
15707265
7.

From hyperglycemia to the risk of cardiovascular disease.

Leiter LA.

Rev Cardiovasc Med. 2006;7 Suppl 2:S3-9. Review.

PMID:
17224875
8.

Effects of a cardiovascular risk reduction intervention with psychobehavioral strategies for Korean adults with type 2 diabetes and metabolic syndrome.

Kim CJ, Kim DJ, Park HR.

J Cardiovasc Nurs. 2011 Mar-Apr;26(2):117-28. doi: 10.1097/JCN.0b013e3181ec02ae. Erratum in: J Cardiovasc Nurs. 2011 May-Jun;26(3):260.

PMID:
21076316
9.

Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome.

Meigs JB, Rutter MK, Sullivan LM, Fox CS, D'Agostino RB Sr, Wilson PW.

Diabetes Care. 2007 May;30(5):1219-25. Epub 2007 Jan 26.

PMID:
17259468
10.

Cardiometabolic risk in Canada: a detailed analysis and position paper by the cardiometabolic risk working group.

Cardiometabolic Risk Working Group: Executive Committee, Leiter LA, Fitchett DH, Gilbert RE, Gupta M, Mancini GB, McFarlane PA, Ross R, Teoh H, Verma S, Anand S, Camelon K, Chow CM, Cox JL, Després JP, Genest J, Harris SB, Lau DC, Lewanczuk R, Liu PP, Lonn EM, McPherson R, Poirier P, Qaadri S, Rabasa-Lhoret R, Rabkin SW, Sharma AM, Steele AW, Stone JA, Tardif JC, Tobe S, Ur E.

Can J Cardiol. 2011 Mar-Apr;27(2):e1-e33. doi: 10.1016/j.cjca.2010.12.054. Review.

PMID:
21459257
11.

Abdominal adiposity and cardiometabolic risk: do we have all the answers?

Haffner SM.

Am J Med. 2007 Sep;120(9 Suppl 1):S10-6; discussion S16-7. Review.

PMID:
17720354
12.

Prevalence of cardiovascular disease and risk factors in a type 2 diabetic population of the North Catalonia diabetes study.

Jurado J, Ybarra J, Solanas P, Caula J, Gich I, Pou JM, Romeo JH.

J Am Acad Nurse Pract. 2009 Mar;21(3):140-8. doi: 10.1111/j.1745-7599.2008.00377.x.

PMID:
19302689
13.

Obesity and cardiovascular disease.

Pérez Pérez A, Ybarra Muñoz J, Blay Cortés V, de Pablos Velasco P.

Public Health Nutr. 2007 Oct;10(10A):1156-63. Review.

PMID:
17903325
14.

Challenges associated with metabolic syndrome.

Spinler SA.

Pharmacotherapy. 2006 Dec;26(12 Pt 2):209S-217S. Review.

PMID:
17125447
15.
16.

Bisphenol A and indicators of obesity, glucose metabolism/type 2 diabetes and cardiovascular disease: a systematic review of epidemiologic research.

Lakind JS, Goodman M, Mattison DR.

Crit Rev Toxicol. 2014 Feb;44(2):121-50. doi: 10.3109/10408444.2013.860075. Epub 2014 Jan 6. Review.

PMID:
24392816
17.

Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes.

Ovalle F.

Clin Ther. 2011 Apr;33(4):393-407. doi: 10.1016/j.clinthera.2011.04.006. Review.

PMID:
21635987
18.

Metabolic syndrome.

Reaven P.

J Insur Med. 2004;36(2):132-42. Review.

PMID:
15301226
19.

Cardiovascular risk prediction in a population with the metabolic syndrome: Framingham vs. UKPDS algorithms.

Zomer E, Liew D, Owen A, Magliano DJ, Ademi Z, Reid CM.

Eur J Prev Cardiol. 2014 Mar;21(3):384-90. doi: 10.1177/2047487312449307. Epub 2012 May 15.

PMID:
22588087
20.

Cardiovascular risk factors (diabetes, hypertension, hypercholesterolemia and metabolic syndrome) in older people with intellectual disability: results of the HA-ID study.

de Winter CF, Bastiaanse LP, Hilgenkamp TI, Evenhuis HM, Echteld MA.

Res Dev Disabil. 2012 Nov-Dec;33(6):1722-31. doi: 10.1016/j.ridd.2012.04.010. Epub 2012 Jun 13.

PMID:
22699246

Supplemental Content

Support Center